The study analyzed data from NVAF patients newly initiating treatment with dabigatran, rivaroxaban or apixaban.
Your search for dabigatran returned 4 results
Boehringer Ingelheim has announced that Praxbind, a reversal agent for the oral anticoagulant Pradaxa (dabigatran etexilate mesylate), is now available in over 2,200 hospitals across the U.S
Real-World Study Compares Treatment Persistence, Discontinuation of Oral Anticoagulants in Afib Patients
Rivaroxaban, a non-vitamin K antagonist (VKA) oral anticoagulant, was found to have better persistence and lower discontinuation rates than, the VKA warfarin and the non-VKA, dabigatran.
Forty-eight percent of atrial fibrillation (AF) patients, who are at the highest risk of stroke, were not prescribed oral anticoagulant (OAC) medication.